RCUS Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals, Inc. has a net margin of -519.23% compared to Arcus Biosciences, Inc.'s net margin of -5701.11%. Arcus Biosciences, Inc.'s return on equity of -66.45% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Arcus Biosciences, Inc. has a consensus price target of $33.22, signalling upside risk potential of 29.62%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 244.83%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Arcus Biosciences, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Arcus Biosciences, Inc..

Arcus Biosciences, Inc. has a beta of 0.747, which suggesting that the stock is 25.335% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.367, suggesting its less volatile than the S&P 500 by 136.662%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arcus Biosciences, Inc. quarterly revenues are $26M, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Arcus Biosciences, Inc.'s net income of -$135M is lower than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.76x versus 502.60x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -519.23% compared to Arcus Biosciences, Inc.'s net margin of 39.21%. Arcus Biosciences, Inc.'s return on equity of -66.45% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Arcus Biosciences, Inc. has a consensus price target of $33.22, signalling upside risk potential of 29.62%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 4.51%. Given that Arcus Biosciences, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Gilead Sciences, Inc..

Arcus Biosciences, Inc. has a beta of 0.747, which suggesting that the stock is 25.335% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.51% to investors and pays a quarterly dividend of $0.79 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Arcus Biosciences, Inc. quarterly revenues are $26M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Arcus Biosciences, Inc.'s net income of -$135M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.76x versus 5.41x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Karyopharm Therapeutics, Inc. has a net margin of -519.23% compared to Arcus Biosciences, Inc.'s net margin of -75.21%. Arcus Biosciences, Inc.'s return on equity of -66.45% beat Karyopharm Therapeutics, Inc.'s return on equity of --.

Arcus Biosciences, Inc. has a consensus price target of $33.22, signalling upside risk potential of 29.62%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 168.62%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Arcus Biosciences, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Arcus Biosciences, Inc..

Arcus Biosciences, Inc. has a beta of 0.747, which suggesting that the stock is 25.335% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.228, suggesting its less volatile than the S&P 500 by 77.201%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arcus Biosciences, Inc. quarterly revenues are $26M, which are smaller than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. Arcus Biosciences, Inc.'s net income of -$135M is lower than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.76x versus 0.33x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -519.23% compared to Arcus Biosciences, Inc.'s net margin of 33.68%. Arcus Biosciences, Inc.'s return on equity of -66.45% beat Merck & Co., Inc.'s return on equity of 39.63%.

Arcus Biosciences, Inc. has a consensus price target of $33.22, signalling upside risk potential of 29.62%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Arcus Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Arcus Biosciences, Inc. is more attractive than Merck & Co., Inc..

Arcus Biosciences, Inc. has a beta of 0.747, which suggesting that the stock is 25.335% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Arcus Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Arcus Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcus Biosciences, Inc. quarterly revenues are $26M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Arcus Biosciences, Inc.'s net income of -$135M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Arcus Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcus Biosciences, Inc. is 10.76x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.